Shattuck Labs Announced Pipeline Prioritization That Includes Discontinuing Its SL-172154. The Company Will Focus On SL-325 And Plans Initial Clinical Development In Patients With Inflammatory Bowel Disease
Portfolio Pulse from Benzinga Newsdesk
Shattuck Labs is discontinuing the development of SL-172154 due to modest clinical results and will focus on SL-325 for inflammatory bowel disease. This restructuring is expected to extend their cash runway into 2027.
October 01, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Shattuck Labs is discontinuing SL-172154 due to modest results and will focus on SL-325 for IBD, extending cash runway to 2027.
The discontinuation of SL-172154, due to modest clinical results, allows Shattuck Labs to reallocate resources to SL-325, which is expected to enter clinical development for IBD. This strategic shift and associated restructuring are expected to extend the company's cash runway into 2027, potentially improving financial stability and investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100